Structural alterations of JAK-2 in melanoma cells leading to reduced MHC class I APM expression and resistance to IFN-γ treatment were detected and overexpression of JAK-2 into JAK-2-deficient cells restored IFN-γ sensitivity and enhanced constitutive MHC class I surface expression in these cells. Here, JAK2 is linked to melanoma.